Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:20:50 18/07/2024 BST			5-day change	1st Jan Change
275 ^CHF	+0.38%		+9.20%	+12.60%

07-17	Health Care Climbs as J&J Rallies - Health Care Roundup	DJ
07-17	ROCHE HOLDING : Obesity could lead Roche’s redemption journey

ROCHE HOLDINGS AG : Gets a Buy rating from Goldman Sachs

January 23, 2020 at 12:16 pm

In a research note published by Keyur Parekh, Goldman Sachs advises its customers to buy the stock. The target price is unchanged and still at CHF 354.

Latest news about Roche Holding AG

Health Care Climbs as J&J Rallies - Health Care Roundup	07-17	DJ
ROCHE HOLDING : Obesity could lead Roche’s redemption journey	07-17
Global markets live: Adidas, TSMC, Vale, HSBC, J&J...	07-17
Roche: results of a treatment for DME	07-17	CF
Roche's Diabetic Macular Edema Therapy Demonstrates Efficacy, Safety in ExtensionStudy	07-17	MT
Swiss Stocks Close Higher as Eurozone Inflation Eases	07-17	MT
Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and A Consistent Safety Profile in Long-Term Diabetic Macular Edema Study	07-17	CI
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- 3rd Update	07-17	DJ
ROCHE HOLDINGS AG : Jefferies remains Neutral	07-17	ZD
Wall Street set to fall as megacap chip, tech stocks tumble	07-17	RE
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating	07-17	ZD
North American Morning Briefing: Tech Lower Again as Rotation Continues	07-17	DJ
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- 2nd Update	07-17	DJ
European shares slide as tech stocks weigh	07-17	RE
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating	07-17	ZD
Roche: share price rises following successful obesity trial	07-17	CF
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- Update	07-17	DJ
Roche reports positive early results in obesity drug trial	07-17	RE
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial	07-17	DJ
Roche's Obesity Drug Lowers Weight in Early-stage Study	07-17	MT
Roche Holding AG Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People with Obesity	07-17	CI
Roche Receives Canadian Approval for Early-stage Lung Cancer Treatment	07-17	MT
Health Canada Authorizes Alecensaro as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer	07-16	CI
ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	07-15	ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	07-15	ZD

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

23/07/2024 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : Obesity could lead Roche’s redemption journey

July 17, 2024 at 05:26 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

274 CHF

Average target price

274 CHF

Spread / Average Target

0.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	+12.60%	250B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.26%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.13%	247B
NOVARTIS AG	+14.35%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Gets a Buy rating from Goldman Sachs

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals